Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
Quick Stats
59.8
AI Score
HOLD0.99
Volume Ratio
Next Earnings
16
+ve Days (30d)
13
-ve Days (30d)
NVAX Stock Summary
Last updated Jan 27, 2026
NVAX is currently trading at $8.845, positioned below its 200-day moving average of $, suggesting bearish momentum. The stock has a 52-week range of $5.01 to $10.64.
Technical Analysis: The 50-day moving average stands at $, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 69.077, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.041, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates NVAX at 59.8/100 with a HOLD recommendation.
NVAX (Novavax Inc) Indicators
Last updated Jan 27, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 69.077 |
| CMF (20) | 0.041 |
| ROC (10) | 26.71 |
| ADX (14) | 46.888 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | 0.68 |
| AROONOSC (14) | 71.429 |
| WILLAMS %R (14) | -12.459 |
| MFI (14) | 75.49 |
NVAX Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
NVAX Price vs Max Options Open Interest
NVAX Max Change In Options Open Interest
NVAX Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
NVAX Daily Out of Money Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
NVAX Daily In the Money Options - Sort by Max open Interest (near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
NVAX Most Active Options by Volume(near term)
2nd February 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Novavax Inc is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
NVAX Moving Averages Analysis
NVAX (Novavax Inc) Simple Moving Averages
Moving Averages are last updated
| Days | MA |
|---|
NVAX Fundamental Analysis
| P/E (Forward) | 2.5846 |
| P/E (Trailing) | 4.7048 |
| Market Cap ($) | 1.4 billion |
| Earnings/Share ($) | 1.88 |
| Net Proft Margin (%) | 0.321 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | 2.1486 |
| EPS Estimate Next Year ($) | 0.2758 |
| WallStreet Target Price ($) | 12.8889 |
| Most Recent Quarter |
Novavax ($NVAX) increases short positions by 1M, reaching 55.2M. Sanofi/Novavax combination vaccines may provide advantage. Sanofi's earnings report next week may reveal information about Phase I/II and mRNA projects. Stock price expected to rise, potentially reaching new all-time highs. Investors optimistic about future growth.
Updated 2026-01-22 17:00:02